Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib

Sorafenib is a clinically useful multiple kinase inhibitor for the treatment of kidney cancer, liver cancer and acute myelocytic leukemia, while it has shown weak efficacy in suppressing breast cancer. Since sirtuin2 (SIRT2) is an important epigenetic regulator and associated with several cancer typ...

Full description

Bibliographic Details

Published in:	Pharmacological Research
Main Authors:	Hua-Li Wang, Xue Ma, Xin-Yuan Guan, Chen Song, Guo-Bo Li, Ya-Mei Yu, Ling-Ling Yang
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Subjects:	SIRT2 Sorafenib Synthetic lethality Breast cancer Combination therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661821006344